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The potential for proarrhythmic responses to the class IC sodium
channel-blocking Octet encainide and Ilecatnide has out been well
described in young patients. Therefore, data were retrospectively
c llected from 36 institutions regarding 579 young patients who
were administered encaiddr, or 0eenlnide for treatment at m .
preset lricnlar tachyeardias (eneainide 06 poll ®eminide 369
patienfr) or ventricular arrhyfhmias (encainide 21 patients,
fiecumide 103 patients) to assess the frequency of proarrhythmia,
cardiac arrest and death during therapy (adverse ecenls), The two
drugs were stroller in regard to efficacy (&ecatnlde 71,1%, encain-
ide $9 .8%) and rate of proarrhythndc responses (flecalnide 7.4% ;
encainide
7
.5'9x). However, patients receiving eneainide more
frequently experien:^d .cardiac arrest (encainide 7.5% vs
.
llecalnide 2 .3%, p < 0.051 or tici awing treatment lencainide
7,5% vs . flecainide 2 .1% . p < 0.05).
Detailed data were provided for 44 patients experiencing one
or rare adverse events
. Patient age, previous drug trials, rm
.
comitant therapy and days of Inpatient monitoring wen similar
Encainide and flecainide are class IC anliarrhythmie agents
that have been shown to be highly effective in the treatment
of ventricular and supraventricular arrhythmias II-Ibl .
However, the potential for adverse effects attributable to
proarrhythmic responses is well recognized for both drugs,
among patients receiving the drugs for either ventricular
(11-17) or supraventricatar (6,9,10 .17,18) arehythmias. Spo.
radic adverse events have also been reported among young
patients receiving these drugs (19--27),
but the overall extent
of these effects in such patients has remained uncertain
because of the relatively small numbers within individual
series.
The Pediatric Electrophysiology Group reviewed the
combined experiences of flecainide and encainide adminis-
tration in young patients among 36 institutions
. The principal
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for patients receiving encainide or flecatnide. However, echocar-
diogrephic left ventricular shortening before treatment was lower
among patients receiving encainide (0.23 ± 0.09) than among
those recehhlg Mainlde (0.34 t 0.06, p < 0.05). Plasma drug
roarentratimrs were rarely elevated . Cardiac arrest (12 patients)
and deaths (13 patients) occurred predmlnantly among patients
with underlying heart disease, particularly among patients receiv
lug fleratnide for supraventrkvlar mrhyrardla (0.3% vs. 0.3%,
p < 0.001).
Fifteen patients with an ostensibly normal heart and normal
ventricular function experienced proarrhythmia during treatment
for supraventrkular tachycardin, Eat only 3 of the 15 had a
cardiac arrest or died. The relatively high incidence of adverse
events should be considered when contemplating treatment with
encainide or fkcainide, particularly among patients with under-
tying heart disease .
fj Am Cull Crvdiol 1991;18:356-65)
goals of the study were to ascertain among young patients
the overall incidence of documented proarrhythmia and
adverse events such as cardiac arrest or sudden death
possibly attributable to proarrhythmia . An effort was
also
made to characterize the specific types of adverse events and
the clinical settings in which they occurred to determine
whether adverse events could be attributed to underlying
heart disease, encessivc drug do~ges, concomitant therapy,
ventricular dysfunction or severity of the underlying ar-
Initial questionnaires. Data were collected by distributing
two questionnaires among members of the Pediatric Electro-
physiology Group
. The initial questionnaire, prepared in
March !989, asked physicians to summarize their use of
flccainide and encainide in young patients. This question-
naire was intentionally streamlined to maximize participa-
tion among the memhers of the group and asked only for the
total number of patients treated, the number in whom each
drug was considered effective, the number with underlying
heart disease and the number of patients experiencing each
of three types of adverse events during therapy : proarrhyth-
rhythmia-Methods
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mia, cardiac arrest and death . Subtotals were provided fur
both encainide and flecainide and for all supraventricular
tachycardias and all ventricular arrhythmias .
Definition. Cardiac arrest was defined as sudden hemo-
dynamic collapse (pulselessness and apnea) recuiring cardio-
pulmonary resuscitation or cardioversion with documented
ventricular fibrillation. Total deaths during therapy included
all deaths regardless of cause or duration of therapy at the
time of
death. Sudden death referred only to death occurring
during therapy under circumstances suggestive of arrhyth-
mia and not clearly attributable to other causes. Prourrhyth-
nria (whether or not asstetated with either cardiac arrest or
death) required ECG documentation of a new arrhythmia or
worsening of an existing arrhythmia by the criteria of velebit
et al. (28), usually during the lit 2 months of therapy . On the
initial questionnaire, proarrhythmia could thus occur inde-
pendently or in association with either cardiac arrest or
death .
Follow-up questionnaire . After the initial questionnaires
were collected, a follow-up questionnaire was distributed to
obtain detailed information regarding each patient who ex-
perienced an adverse event . This detailed questionnaire was
completed only for those patients experiencing an adverse
event ; comparable data were not collected for those patients
not experiencing an adverse event during effective treatment
or in whom treatment was discontinued because of ineffi-
cacy. Particular emphasis was placed on determining
whether these events could be attributed to the type of
arrhythmia being treated, underlying heart disease or abnor-
mal ventricular function, excessive dosing or concomitant
therapies being administered at the time of an adverse event .
Data obtained thus included age, weight, height, body sur-
face area, anatomic and functional cardiac diagnoses (includ-
ing previous cardiac surgery or suspected cardiomyopathy)
and a qualitative (and, when available, quantitative) estimate
of systemic ventricular function before treatment . All known
arrhythmias before treatment were listed, and data on per
manent pacemaker implantation and indications for pacing
were provided . The indications for therapy with encainide or
flecainide were also stated, including data on all antiarrhyth-
mic drugs previously administered. Dosing information in-
cluded the frequency of administration, days of inpatient
monitoring, apparent efficacy of treatment and any other
cardiovascular drugs being administered concurrently . Fi-
nally, the circumstances of the adverse event were de-
scribed, including duration of treatment, plasma drug con-
centrations closest to the date of the adverse event, rhythm
documentation when available, treatment provided in re-
sponse to the event and the outcome of treatment.
Arrhythmia classification . A uniform classification was
utilized for rhythm diagnoses . Sapeavenrrirular rachycar-
dias included all reciprocating tachycardias, including atrio-
ventricular (AV) reciprocating tachycardia, reentry within
the AV node and the permanent form of junetional recipro-
cating tachycardia; primary atrial tachycardias, including
atria) ectopic tachycardia, atria) flutter or intraatrial reentry
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and aural fibrillation; and junctional ecl.opic tachycardia .
Vanrriculur
arrhythmia,
were described as complex ventric-
ular ectopic activity, spontaneous sustained ventricular
tachycardia, spontaneous ventricular fibrillation or ventric-
ular tachycardia or fibrillation induced at electrophysiologic
study (according to each institution's Criteria) .
Risk classification
. The apparent risk of
each patient's
arrhylhmias (before treatment) was identified by each indi-
vidual investigator. These were categorized as low risk,
presumed high risk or definite high risk. Presumed high risk
(according to the individual investigator) could be cited on
the basis of underlying heart disease or arrhythmia that had
been previously associated with severe hemudynmnic com-
promise, or both. Definite high risk required either previous
cardiac arrest or a previously demonstrated lethal arrhyth-
mia (spontaneous or catheter-induced sustained ventricular
tachycardia or fibrillation).
Statistics . Statistical analysis of parametric data utilized
Student's unpaired r test . Nonparametric comparisons were
limited to 2 x 2 chi-square analysis with Yates' correction
for continuity or Fisher's exact test where appropriate .
Results
Initial Questionnaire (Table 1)
The initial questionnaire was completed by 36 investiga-
tors in the United States, Canada, Great Britain and The
Netherlands who had administered to 579 young patients
either flecainide (472 patients) or encainide (107 patients),
mostly for treatment of supraventricular ventricular nrrhyth-
mias (flecainide 70% . encainide 00%v) . Congenital heart dis-
ease was present in 137 of these 579 patients (108 receiving
flecainide vs . 29 receiving encainide, p = NS) . Data on age,
gender and specific types of underlying heart disease were
not available for all 579 patients
. Both drugs were highly
effective. Overall efficacy was slightly greater for flecainide
than for encainide (71 .4% vs. 59.5%, p < 0.05), primarily
reflecting the slightly greater efficacy of flecainide for su-
praventricular taehyeardias (70% vs . 57%, p c 0.05) ; ven-
Iricular arrhylhmias were similarly responsive to each drug .
Overall proarrhythmia . Overall proarrhythmia was fre-
quent (7 .4%) and was similar for both drugs (encainide 7 .5%
vs. flecainide 7 .4%, p = NS) . There was no difference
between the mean rate of proarrhythmia in patients with
supraventricular tachycardia (7 .7%) and that in patients with
ventricular arrhythmia (6.4%, p = NS) . Likewise, proor-
rhythmia due to each drug was comparable among patients
with supraventricular tachycardia (encainide 6 .9% vs .
flecainide 7 .9%), and those with ventricular arrhythmia
(encainide 9 .5% vs. flecainide 5 .8%, p = NS).
Overall cardiac arrests and deaths . In contrast to overall
proarrhythmia, the proportion of cardiac arrests and total
deaths was greater among patients receiving encainide than
among those receiving flecainide (cardiac arrests 7 .5% vs .
2 .79( deaths 7 .5% vs . 2 .1% ; p < 0.05 for both) . This
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Table 1 . Summarized Results From 30 Pediatric Centers Responding to the Initial
Questionnaire
-9 < 105,
encainide ver,us Aeainide . SVT =
a,praveaMcuar 7chycardia nr anM1ylM1mias ; VT - 0mre,aar
1achvcardia er anhylhm6,,
difference remained significant when comparing treatment
for supraventricular tachycardia (cardiac arrest 6 .9% vs.
1 .9%, death 6 .9% vs. 1 .4%, p < 0.05 for both], but not for
ventricular arrhythmia .
Overall adverse events. From the initial questionnaire, up
to 80 adverse events were reported . However, the question-
naire design did not allow determination of the total patients
affected, since an individual could experience any type of
adverse event individually orcould experience a single event
fulfilling the criteria for sudden death, cardiac arrest and
proarrhythmia . Thus, the follow-up questionnaire allowed
an indirect determination of the overall number of patients
affected .
Underlying heart disease, Proarrhythmia was similarly
common among patients with congenital heart disease and
those with a structurally normal heart 110°)3 vs . 6.1% . p =
NS) whether they were receiving flecainide 112,5% with
heart disease vs . 7 .3% without, p = NS) or encainide (3 .67°
With heart disease vs . 13 .5% without, p = NS) . However,
the proportion of cardiac arrests and total deaths during
flecainide treatment for supravcotroculartwhycarda was
. far
greater among patients with congenital heart disease [cardiac
arrests 8,3%p vs . 0.3% . P
e
0 .001 ; deaths 6 .8%p vs. 0 .3%. p <
0 .001) . A similar relation between deaths or cardiac arrests
and congenital heart disease could not be demonstrated for
either drug in the treatment of ventricular arrhythmia,
Follow-Up Qaeslionnaire : Adverse Events
(Tables 2 to 51
From the 36 institutions responding to the initial ques-
tionnaire, follow-up data were provided by 14 of 17 institu-
tions reporting one Or more patients who experienced an
adverse event. Thus, individual data were made available for
44 of the approximately 50 patients who experienced one or
more of the adverse events (12 receiving encainide, 32
receiving flecainide, Table 2). Those experiencing adverse
events during treatmcm with encainide or flecainidc were
similar in regard to
age, duration of therapy, the number of
prior antiarrhythmic drugs and the number of coadminis-
tered cardiovascular medications, However, echocardio-
graphic left ventricular shortening fraction (before treat-
ment) was significantly lower among those patients given
encainide (D.23 m 0.09 vs . 0 .34
t 0 .06, p < 0.05) .
Association with suspected risk factors.
Multivariate or
univariate analyses to identify individual risk factors were
not feasible, because the questionnaire design provided
detailed individual information only for those patients who
experienced an adverse event, However, the distribution of
several suspected risk factors could be examieod among
these patients.
Type of arrhylhmia and high saw low risk (Table 3) .
Among the 44 patients experiencing an adverse event, 34
were being treated exclusively for supraventricular tachy-
cardia (10 receiving encainide, 24 receiving flecainide, with
the remainder being treated for ventricular arrhythmia alone
(I receiving encainide, 5 receiving flecainide) or in combina-
Table 2 . Clinical Characteristics of the 44 Patients Who
Experienced an Advrrse Fvent M ring Encainide or
Feecainide Treatment
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'p C 0.03, -amide virus xxainide . Values are expressed as mean
values ! SD or mean values and rangy LVSF = leh ventricular shortening
fraction .
No . 0iltcas Proarrhylhmla CardiacAnual Deaths
Encainid.
5VI 8b 4915741 616 .9141 616 .
	
1' 6169031'
V1 21 15014) 219 .541 2195.7) 219 .5.9)
Tidal 107 6416731 x17
.54) 3179507 x1155; •
F15-.d,
WT 169 29D1r31 2917 .94) 7117:21 51 1 .4.01
VT 101 78170131 615991 4131 514 .1
T.W 472 331 1719+ 31 17 .49) 11(2 y4) 1012 .141
Comhmed 16901,
SVT 455 3571)6871 3517 .7`55 1312 .E 1 111LJ41
VT 174
9317541 8(6 .4'5) 614 .1)3) 7)5 .630)
Total 579 JUI169'51 41(7p"k) 1913 .741 is 6J4)
Fkeahlide Encainide
Age Imeun ; range) 9.9 yr, 4 days-26 yr 1.4 or; 36 days-22 y.
Dace
mgtkg per day 2 .2 } t 8 2.3 1 3
.2l"? per day 102 34 144 + 45
LVSF (kl 34 ! 61 23 ± 9
Days munttaral in the . ? 4 7 -- 3
twspiml Irn.)
Days from Stan of uealenit to 161 ; 0-700 83; 2-420
adverse
111 .1 (11- age I
No . or Previousaotia,hylhmic 2.9± 1 .7 3 .4 .0.9
medications leer I atienu
No . of patients receiving 1401' 5)13
additional antiarmythmlc
drugs
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Table 3. Rhythm Diagnoses thrfore treatment) Among
44
Patients
Who Experienced an Adverse Event During Treatment With
Encainide or Flecainide
'Additional arrnythmies leeen(O, within eh+ mdao-earioiae 1AVl node,
two pariepts : Camplek eemrt.,c r
temp,
adivity . Ihrre pahedh'. sparllana
e0s sentrietlr tachycardia . one patmnll. tone parcel xith cengerital long
QT syndrome. AVNRT - reenlrv widen the 9V node
. AVRT = AV
reciprocating ulehyenPoia loll annaolromrF : EPS = decuuphysiuugic study .
PIRT = permanent junctional reciprocating tachycardia,
lion with supraventricular tachycardia ( I receiving encain-
ide, 3 receiving flecai side) . Of the 34 patients being treated
for only supraventricular tachycardia 17 were presumed to
be at high risk because of associated heart disease or poor
hemodynamic state, whereas 16 patients were at presumed
low risk because of an ostensibly normal heart and nonlethal
arrhythmia (t patient was considered to be at undetermined
risk) .
Four of six patients with exclusively ventricular arrhyth-
mia and two of four patients with multiple atrial and ventric-
ular arrhythmias were believed to be at definite high risk for
sudden death on the basis of long QT syndrome (one patient)
or previous cardiac arrest m syncope with documented
ventricular tachycardia (spontaneous to three patients . in-
duced at etectrophysiutogie study in four) . Four other pa-
tients were presumed to be at high risk for sudden death
because of the presence of complex ventricular ectopic
Table 4. Distribmion of Cardiac Diagnoses Among 44 Patients
Who Experienced an Adverse Event Daring Encalance nr
Flecainide Administration
'Includes
Ann
paarnls wim hyyeneuphic cardonyorahe. tirtbder ene
ptienl d ec underwent arenpled sunyol accessory pan,way elation, tlndudes
one patient with the lorggn syn,devnx and two panens wiN primar y rum is. am
etyshnaa-inducedl cuaerneva:hy . LV - tea vevnicatar.
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Table 5. Cardiovascular Drugs Being Administered Concurrent
With En-rile or Flecainide Among 44 Pati_nls Who
Expcricrccd AT, Adverse Event During Treatment
activity in nisociotion with underlying heart disease or
ventricular tachycardia at etectrophysiologic study, or both .
Ventricular dysfunction and underlying heart disease
('table 4). Among the 44 patients who experienced an ad-
verse event . 29 had underlying congenital (excluding a
manifest pre-excitation syndrome) or funetiana! heart dis-
ease (19 of 32 receiving neeainide, 10 of 12 receiving encain-
idel
. This group included 14 patients who had undergone a
previous operation for congenital heart disease or accessory
AV connections (4 receivjng encainide, 10 receiving flecain-
idel. There was also objective or subjective evidence of
systemic ventricular dysfunction in 14 of the 29 patients .
including 4 whose dysfunction was attributed to c%trunic
tachycardia. Fifteen of the 44 patients had an
-
'ostensibly
normal' heart with no identifiable functional abnormality
(other than the primary arrhythmia)
.
Dosing and plasma concentration
. All patients were hos-
pitalized
during iniliatic-
0
of treatment for an average of
6 .4 a 3 .7 days (range 0 to 21) . Doses at the time of the
adverse events were generally within previously recom-
mended ranges for young patients: o5 .7 mg/kg per day
Is 120 mglm'' per day) for 11 of 12 patients receiving cncom-
ide and <6 mgfkg
per day (<200 mglm e per day) for 27 of 32
patients receiving fleeainide (20,24-26) . The maximal
encainide dose reported was 6 .7 mglkg per day (175 mg/m2
per day) . ,rd the maximal Becainide dose reported was
12 .) mglkg perday (332 mbar' per day
) .
No differences were
evident between flecatnide dose and the type of adverse
event (Fig
. 1) .
Flecainide plasma concentrations were available from 27
of the 32 patients experiencing an adverse event (mean 550
320 ngml) . and were elevated C>1,000 nglmi) in only 2
patients 1Fig . 1). Flecainide concentrations at the dual dose
were no different among 10 patients experiencing an adverse
event after the 1st 2 months of therapy (590 ± 400 ng/mll
compared with those experiencing an early adverse event
(520 x 240 nglml) . Concentrations were likewise similar
among patients experiencing proarrhythmia only (414 *_
267 rpiml), cardiac arrest (490 no 275 nglml) and sudden
death (620 ± 160 ngiml
. excluding a single markedly elevated
result of 1 .710 nglml( . Plasma concentrations for encainide
and the active metabolites were available in only 3 of I I
patients ; none of these concentrations were elevated (cor-
Encainide Flecainide
Supmvemricular
mchycardias
AVRT
AVNRT
A1rd flutter or fibrtlniont
PART
Fetapic alrinl lethytardia
Vtnmtuler latt)eardic'
IVTI
Complex ectanerhychm
SWntanwussunainedVT
EPS-induced cssrained 4T
I
S
2
2
2
I
I
D
3
I I
0
I+
Encainide Fleginlde
Ditvein o
12
taucmnnnide - 1
arianwahine usage a
Aniauar ale I
Diurni :=een. 3
lnnunpic agntc I
NOC
16
E, -,,d,
14 -de
Congenital head discanc
No nervous cardiac surgery 5
Previous cardac surgery
4 10
No congenital heart disease
Normal LV Sandier 31
Abnormal LV function '
Mmcdlancees I
0-
Proerrhythmia Cardiac
Arrest
Sudden
Deem
Figure 1 . Plasma concentrations it. 26 patients experiencing adverse
responses during treatment with flecainide . Two patients had a
concentration above the upper recommended therapeutic range
(dotted line . . . ) . The remaining parents had widely varying can-
centrations within the therapeutic range, regardless of the type of
adverse event reported.
recting for extent of metabolism to 0-desmethyl encainide)
(29).
Concomitant therapy (Table 5) . Twenty-five of the 44
patients experiencing an adverse event were receiving one or
more cardiovascular medications in addition to encainide (9
patients) or flecainide (15 patients) . Digoxin was the most
commonly coadministered medication (18 patients)
. The
coadministration of other drugs was not examined among
patients who did not have an adverse event .
Early versus Late adve
:-ne events. An adverse event oc-
curred within the 1st 2 months (loran 9
.9 days) in 31 of the 44
patients (22 receiving flecainide, 9 receiving encainide),
including 2 patients who developed incessant ventricular
lachycardia with intravenous flecainide administration
.
Twenry-two patients experienced on adverse event during
inpatient monitoring, including 10 who experienced cardiac
arrest (9 patients) or died (I patient) . Nine other patients
experienced apparent proarrhythmia (two patients), cardiac
arrest (one patient) or death (six patients) soon after being
discharged on treatment .
Death (six patients) or cardiac arrest (three patients)
occurred late (>2 months) after the start oftreatment in nine
patients . Although only two of these nine patients were at
definite high risk, seven had underlying congenital heart
disease that had been surgically treated in six . All seven
patients were being treated for atria) flutter either alone (four
patients) or in combination with ventricular arrhythmia
(three patients), and all had a ventricular demand pacemaker
before treatment
. One additional patient with hypertrophic
cardiomyopathy died late while receiving flecainide, and one
with an "ostensibly normal" heart had a late cardiac arrest .
Thus, eight of nine late-occurring lethal or potentially lethal
adverse events occurred in patients at either definite or
presumed high risk .
JACC Vol. Ix, No, 2
Aueust 1991 :356-65
Four other patients experienced an adverse event after
the Ist 2 months of therapy that their reporting physician
considered to be suggestive of proarrhythmia . This group
included one patient who developed new incessant ventric-
ular tachycardia (without cardiac arrest) 85 days after the
start of flecainide therapy; tachycardia did not recur after the
dose was decreased . The remaining three patients experi-
enced either marked exacerbation of AV reciprocating
tachycardia or incessant supraventricular tachycardia.
Type of adverse event and apparent risk (Tables 6 and 7).
Patients who died or were successfully resuscitated from
cardiac arrest are listed in Table 6 . Death was sudden with
no other identifiable cause in 12 of 13 patients and was thus
presumed to be due to arrhythmia . The remaining patient
died of progressive congestive heart failure during treatment
with encainide rather than from an arrhythmia . Three of the
patients who died suddenly or experienced cardiac arrest
within the 1st 2 months of treatment were at known high risk
as characterized earlier; two other patients known to be at
high risk died or survived cardiac arrest late (407 and 387
days, respectively). Sixteen of the remaining 20 deaths or
cardiac arrests occurred in patients presumed to be at high
risk (or undefined by the reporting investigator) . Thus,
patients either known or presumed to be at high risk ac-
counted for 21 of 25 lethal events possibly related to proar-
rhythmia.
Only 4 of the 25 patients experiencing cardiac arrest or
death had no underlying heart disease and were presumed to
be at low risk during, treatment for supraventricular tachy-
candies (Table 6) . These events were clearly related to
treatment in at least three of these four patients, all ofwhom
were being treated for supraventricular tachycardia . One of
these three patients died 22 days after beginning treatment
with encainide and two patients experienced cardiac arrest
during intravenous flecainide administration (one of whom
later developed incessant supraventricular lachycardia dur-
ing oral flecainide therapy). A fourth patient had a cardiac
arrest 23 months after beginning flecainide therapy (for
tachycedia due to reentry within the AV node) despite a low
therapeutic flecainide concentration (352 nglml) at a dose of
6 .5 mglkg per day (249 mglm2 per day). Despite this late
occurrence, the cardiac arrest was attributed to flecainide,
and the patient experienced no subsequent cardiac arrest
over 20 months after flecainide was discontinued.
Twelve of18 patients who experienced proarrhythmia not
resulting in cardiac arrest or death developed incessant
sapraventricular lachycardia (wide or narrow QRS com-
plex) during flecainide treatment for paroxysmal AV recip-
rocating lachycardia (Table 7) . Four other patients devel-
oped new ventricular tachycardias during treatment for atrial
flutter (two patients), permanent junctional reciprocating
tachycardia (one patient), or reentry within the AV node
(one patient)
. One patient was considered to have proar-
rhythmia at electrophysiologic study and another developed
high grade AV block and bradycardia during encainide
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Ta61e 6
. Data on 25 Patients Who Experienced Death or Cardiac Arrest During Encainide or Flecainide Administration
`Diedofprogressi engeslivehea,tfaihue noilerlrealmenlwdhenainidewasbegun, sCardizeanestdudnginirdvenausadminisnasion
.AET=atrial
ectopic rachyeard,n : AF
a
arch) flutter ar hhrillntieo: AV = atnnvenldcuhr:AVNRT = reentry within the AV node_ AVRT = AV reciprocating tachycardia;
d-TGA and I-TGA - destro-and levo-transpoeitieo .11 the great arteries, respeaieely . FPS- VT = ventricular mehycardia induced at •lectrophysioloricstudy
only : HOCM = I',ypenrophic
obstructive
cardiomyopnthy* htn -- hypertension: no not eerieSle : PA = pulmonary artery : PDA - patent duptus aneriosus:
PIRT = pennanem junctierat reciprocarirg tachytardia' . 1' . .d 2' - primary and veondary . respectively; ceo-gain tithan - syatemlc-pulmonary artery Shun:
VSD = ventricular serial defect ; VT - ventricular tachycardia
.
therapy ; the latter patient had preexisting left bundle branch
block .
Discussion
Incidence of
adverse effects
of antiarrhythmic therapy.
Because of scattered adverse experiences among various
pediatric centers, and subsequently the Cardiac Arrhythmia
Suppression Trial (CAST)
report (131, closer scrutiny of
encainide and flerainide appeared warranted . By utilizing
two separate questionnaires to limit nonrespunse bias, we
were able to identify approximately 50 patients from 17
pediatric institutions who had experienced an adverse event
during therapy . This represents approximately 8 .617, of the
579 patients from the 36 investigators responding to the
initial questionnaire . As noted later, this figure probably
reflects the type of patient receiving the drugs as much as it
reflects the drugs themselves.
This study represents the first collaborative examination
of proarrhythmic events among young patients receiving
amide and flecainide, Assessment of potential risks of
amiarrhythmie drugs in young patients is inherently difficult,
because the small number of patients relative to the diversity
of diagnoses limits attempts at patient stratification as a
means of characterizing outcome
. Furthermore, the poten-
tial influence of age and development on adverse drug effects
remains largely unexplored . For most drugs, the only option
has been to project apparent
risk factors observed in adult
series to younger age groups.
Risk factors for adverse events. The present study sup-
ports both the extrapolation of risk factors for encainide and
flerainide previously reported among older patients (16) as
well as the need to modify or expand these risk factors as
applied to young patients
. As might be anticipated, lethal or
potentially lethal events during therapy with encainide or
flecainide usually occurred in patients who had more serious
underlying arrhythmia, impaired systemic ventricular dys-
function, underlying heart disease or were otherwise at
Drug
Age Rhy,hm Care's Diagnosis
Pre-us
Surgery
Ventricular
Dysfunction Risk
Death
I Encainide
13 ma
. ART Putmmury atrasm. VSD Sysvpolm than, Mademte PraSemcd nigh
2 En<einlde 13 7 yr EPV-V I HOCM None High
I Freainide 12 .3 yr PIRT I'ardmm)npa,hy R'S S-- Presumed high
4 EneaiMde 9.4 yr At . VT HOCM None High
5 Encainide 3 .7 yr AF it FGA Mustard Moderate Presumed high
Shoeonidc 22.1 yr
AFT N .- I Nnne
Inw
7Flecainide
na
F opicacuv
:y HOCM
None Resumed high
8Flecainide na AF J-TGA
Mo>lud
Mild Undefined
9 Flecainide
IA 0 yr
VT
Cardinmcnpa,hy i I'1
Nunr High
10 Fl-mad, 74A yr AF 'rneacpld a Glenn . Fom.n Moderara Pres med high
II Ileeainae
14 .1 yr FPS .V'I Cardmmppe,hy
III None High
12 l-lrro unde
4 .2 yr
At
VSD, P.1mon-ary hln VS]) span
Mild
Undefined
13 Flecaiaide 17 .4 yr AVNRT, AF . ectopic Tnralogy of Sallor
Te,ralngy rep-
MoIo,ate Pusua,ed lab
activity
~Y Cardiac Arrest
14 Encainide ZI .6 yr AF Normal Moderate Presumed high
15 Encainide to . . AVRT Normal PDA ligation None Premmed high
16 Encainide AF d.TGA Mustard Moderate Presumed high
17 Encainide 7.5 yr AVNRT AV septa defect PA hat Moderate Resumed high
16 Flecairide 9.0 yr LQTS Long QT syndrome Nova: Resumed high
19 Flecainide 15.6 yr AF, ectopic activity Single vemndc None Resumed high
20Flecainide 10.6 y, AVNRT Normal None Low
21 Fleeainide 4.6 yr' PIRT Normal None Low
22 Fleeainide 6.5 yr AF d .TGA Mustard None Presumed high
23 Flecatold, na AVRT I-T(jA . VSD Homogra0 Mild Presumed high
24 Fiecainide 1 .8 no+ AVRT Normal Moderate Low
25Fkcainide 13.Oyr AF VSD VSD None high
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Tubk 7
. Data on 15 Patients With Supraventdculer Taehycardia wad an Ostensibly Normal Heart Who Experienced as Adverse Event
	O-dcsnmthyl-encainlde (cocemidt, 10 np/mIL
°I-scant
supnaoealricularlachycardia (SVT) during intravenous aecainide. SCardiac arrest Ivcntricular
taehycardial during intravenous to aieide ; subsequent incessant evpraventrxular rachyeadia during anal Secainide therapy . WPW - WolO-Parkinson-White
syndrome. Other abbreAarions as in Table 6.
known or suspected high risk of sudden death . Nevertheless,
similarly severe adverse events occasionally occurred in
patients presumed to be at low risk on the basis of nonlethal
underlying arrhythmia and an "ostensibly normal" heart .
Furthermore, proarrhythmia not resulting in cardiac arrest
or death occurred frequently even in such low risk patients .
Proarrbythmta . Proarrhythmia could not be attributed to
excessive dosage or plasma concentrations in the majority of
adverse events, Three of the patients with an "ostensibly
normal" heart with severe hemudynamic compromise (clas-
sified under cardiac arrest) were receiving intravenous ther-
apy for AV reciprocating taehyeardia, one of whom also
later experienced proarrhythrnia (incessant AV reciprocat-
ing tachyeardia) during oral therapy (Table 7) . Several items
of potential interest in predicting potential risk for proar-
rhythmia in individual patients were not examined, including
the potential role of changes in QRS duration, exercise
testing or follow-up etectrophysiologic testing (12,15,36) .
Limitations of the study. This study suffers from several
limitations because of its retrospective nature . Patients were
not randomized to receive flecainide or encainide, limiting
any direct comparison of these two drugs with respect to
either efficacy or potential risk. Indeed- encainide appeared
to be reserved predominantly for patients with impaired
ventri,alar dysfunction, probably accounting far at least part
of the higher incidence of cardiac arrest and death associated
with its use . Furthermore, 35 of the 36 participating investi-
gators reported using flecainide whereas only 15 investiga-
tors had used encainide, Presumably, patients who were
administered encainide rather than flecaimde at these insti-
rations because of ventricular dysfunction might have re-
ceived alteraative treatment at other institutions, possibly
with similarly adverse outcomes . The lack of a comparable
prospective or histoncal control group receiving either no
recC V.I . Is, No. 2
Aueus, 1991 :356-65
therapy, placebo therapy or alternative therapy limits the
ability to determine the relative impact of flecainide or
encainide on mortality or morbidity in this group of patients .
The use of two questionnaires also presented certain
limitations to the study as well as possible strengths. The
goal of minimizing the information collected in the initial
questionnaire in order to maximize the number of institu-
tions willing to contribute their experience appeared to be
successful
. A high rate of participation was considered
essential to fulfill the primary objective of assessing the
overall extent of adverse events during encainide and
flecainide administration. The use of the second detailed
questionnaire provided a qualitative alternative to examine
the spectrum of patients in whom both lethal and nonlethal
adverse events had been observed. Although the statistical
significance of these observations is tentative, the simple 2 x
2 comparisons help support the general finding that proar •
rhythmic was common among all groups but cardiac arrest
and sudden death usually occurred in patients with underly-
ing heart disease .
Finally, a concise defi,eilion of peoarrhythmia is itself
problematic in
the retrospective study we report. While
limiting adverse events attributable to proarrhythmia to
those occurring within the 1st 2 months of therapy has been
advocated (28), data from CAST (13,31) demonstrated a
continued decline in survival
in the encainide and flecainide
treatment group compared with placebo well after the Ist 2
months of treatment . Thus, adverse events that occurred
after 2 months under circumstances highly suggestive of
true proarrhythmic responses were included in this report.
Nevertheless, the proportion of cardiac arrests or sudden
death, during or after the tat 2 months that truly represent
proarrhythmia responses to therapy remains undetermined.
Drug Ape
Rhythm
Daonasi
Cowmrem
Therapy Risk
Floama Encainile or
FkeamidrLeant
Inlddfl
Adverse Event
orSpeeiSc
Proanhythmia
Encdnide 22yr AET soar 160• Sudden death
Enceinide 1 .2 yr .AF . AVNRT Amiodarone Presumed high - AV block. bndywrdia
Fccainidc 00yr .AVRT Rigasin taw 250 WOo (5R5 SOT
Flecaialde
15 day, .AVRI,WI'W Dnaopgtamide
Stanford high
I Wide QRS SVT
Fecainidc 26.5 yr AVRT . WPW - Law - Incessant SVT
Flecainlde 9days AVRT - Law 312 Incessant SVT°
Fleeainlde 1116yr AVNRT - Law 352 Cardiac ales!
Fl-m& 46 y , P1RT - raw 6a3 Ieee5,en1SOT.IVTI!
Fleuinide 17 .9 yr AVRT, WPW - Law IIt Imenam, SVT
Flecamtde 2 .3 run AF Digosv, Law 620 Wade QRS SVT vs. VT
Flccainidc 6day, AVRT, WPW - Presumed high 290 lacessantSOT
Flccainidc 7da y. AVRT - tow -- InctssacnSVTt
Flecainidv 12, AVRT, WPW Propranolol Lo, - Incessant SVT
Flccainidc na AF - Low 500 AggmvatedSVT
Flccainidc 2.1 ye AVRT. WPW AVRT, WPW Low
- WsdrQRS SVT
JACC V .I. 18 . No. 2
August 1991 :356-65
Table e
. Proatrhythmia Rates in Selected Series of Adult Patients Treated With
Encainide or Flecainide
Cardiac Aneass
or Deaths'
(no . of patients)
52 of 1,245
8 of 193
as fmm tent
no from as,
ro from let
na from text
na front text
2of55
na from text
na from text
10 of 31
1or64
'Nol necessarily aanbmed to prvurhythma. responses, tyouled data from multiple it- .sligaturs . VF =
ventricuLa, fibrillation; other abbreviation as in Tables 6 and 7 .
Comparison with previous reports of proarrhyrhmia (Ta-
bles
8 and
9). Previcus
studies (8,11,12,14-16,32,33)
identi-
fied proarrhythmia in 7% to 16% of patients receiving
encainide and 3% to 16% receiving flecainide . These were
predominantly studies of patients receiving treatment for
ventricular arrhyihmias . These and other studies were
pooled by Morganroth and Horowitz (15,16) to provide
sufficient numbers (1,245 patients receiving encainide . 1 .330
receiving flecainide) to identify risk factors for proarrhyth-
mia, including presence of structural heart disease (including
valvular, atherosclerotic or cardiomyopathic processes) and
sustained versus nonsustained ventricular tachycardia .
Several reports (5-7,10,34) in adults have suggested that
patients with supmventricular arrhythmia or nonsustained
ventricular laehycardia and an otherwise normal heart may
be at very low risk for proarrhythmia. The current study
suggests that the infrequency of proarrhythmia in such
patient groups may largely reflect, rather than actual protec-
tion from proaeThythmia, the relative infrequency with
which encainide or flecainide has been administered for
'Contributed to the present study . Abbreviations as in Tables 6 and 7 .
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these arrhyihmias compared with more serious ventricular
arrhythrLias . Instead, this study supports Morganroth's ob-
servation (16) that the severity of proarrhythmic responses
was more closely related to risk factors than to overall
incidence of ptoarrhythmia . Furthermore, as in Morgan-
roth's report (16), the risk of adverse responses appeared to
vary more among patients receiving flecainide than among
those receiving encainide, although direct comparison of the
two drugs is tentative .
Clinical implications, Despite the justified concerns gen-
erated by the CAST report and the present report, several
questions remain unanswered . The extent to which these
results apply strictly to encainide and flecainide remains
undetermined . For example, patients in the present study
with atria! flutter after surgery for congenital heart disease
had generally been treated unsuccessfully with multiple
medical regimens before receiving encainide or flecainide .
Yet both encainide and flecainide were quite effective in this
drug- rfractory group
. A less effective antiarrhylhmie agent
with a similar tendency to proarrhythmin might have pre-
Table 9. Pmarrhythmia Rates for Encainide and Flecainide Previously Reported From
Pediatric Centers
tnvcshgalom
(Ref) Dog
No. of
Patienls
Anltythmtas
Treated
Proarrhynmia
(9(
Strasbu',<t et d.(20) Encainide 15 SVT . VT 13
Till or al . (23)' Flreninide 13 SVT 8
Ward e(d
.(21) Flecaimde
5
AVRT
0
Ziegler et al, 124(' Flecuinide
29
SVT, VT
7
Till et al
. (27)' Flecainide 27 SVT
(minedtypesl
9
Mono et al
. (25) Flecainide 16 SVT (mixed types) 0
Perry et al
. (26)' Fl eeainide
63
SVT. VT 8
Investigators
(Ref)
Number of
Patents
Arrhythmias
Treated
Proarrhylhmia
(`AI
Encainide
Soyka et al . 116( 1,2455 VT 9
Encainide-Vertneular 193 VT 7
Twhycardia Study Group (8)
Slanlon
I al (141 110
VT, VP 12
Prytlowsky et d . (q 19 AVRT 0
Flecainide
Merganmth (16) 1330' VT. VF 7
LcI eI al . (33) 38 VT 10
Stamon el al . 1141 25
VT . V F 4
Anastassaa-Napa et a1. 112) 55 VT, VF 13
Fac1Sini et al. (341 21 VT 0
Rerns el al . (6) 39 A ET. AF 20
Epstein m al . 1101 31 SVT (mixed typed 19
Arderson et al . (9) r l AF II
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seated even greater risk to these patients because failure to
successfully treat atrial flutter has been associated with
mortality in such patients (35) . Such a possibility is sup-
ported by mela-analysis of multiple prospeclive placebo-
controlled tnals (36) that demonstrated an overall increase in
mortality among adult patients treated with quinidine far
prim fibrillation.
The infrequency of lethal
events
in putientr with a struc-
rurally normal heart and normal ventriadarfunrtion being
treated for supravenlricular tachycardias may support the
view of a low risk patient profile . That is, although proar .
rhythmia was common among all risk groups, cardiac arrest
and death were uncommon among patients with an other-
wise normal heart receiving flteainidc in, supravcntricular
tatdnycardia . Only two such "normal" patients in the entire
study experienced a lethal event
if
only those receiving oral
therapy are considered, This observation supports the find-
ings of Perry et al
. (26) . whose )rodents were included in the
present report.
The potential role of colnhmntion drag regirnerls in lire
patients who had an adverse event remains undetermined .
The frequent use of other drugs in combination with
flecainide and encainide supports the drug-refractory nature
of these patients' arrhythmias . Because both the resistance
to therapy and the risk of adverse events during therapy may
be related to underlying heart disease, it would be extremely
difficult to assess any potential incremental risk ofcombina-
tion therapy without prospective randomized analysis .
Perhaps a more difficult issue is whether long-term ad-
ministration of these drugs imparts a cumulative risk of
prtmrr)tyihmiu or deurk in either low risk or high risk
patients who are apparently tolerating the drugs well, The
long-term follow-up data were not sufficient to assess any
potential long-term cumulative risk . While the late cardiac
arrest in a single patient with lachycardia due to reentry
within the AV node is worrisome, this was an otherwise
atypical event in this large study population . In general,
having a supraventricular tachycardia and an ostensibly
normal heart would seem to impart a lower risk for serious
adverse events, but may not exclude the potential for late
proarrhythmic responses during treatment .
CRnclusinns . The frequency of proarrhythmia, cardiac
arrest and death in this study reinforces the need to contin-
ually reexamine the indications for initiating and continuing
anliarrbythmic drug treatment (33) . In the present study,
suppression of asymptomatic ventricular ectopic activity or
ventricular tachycardia induced only at electrophysiologic
study was cited as an indication for therapy in eight patients
who subsequently experienced an adverse event, possibly
attributable to proarrhylhmia . As in adults with iechemic
heart disease, the merit of treating certain asymptomatic
ventricular arrhythmias in an effort to prevent sudden death
among young patients will require further scrutiny . Ulti-
mately, prospective randomly assigned trials in stratified
patient groups may be necessary to define
risks and benefits
of various antiarrhythmic therapies .
IACC Vol. In, No. 7
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